{"id":"dl-alanine","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"alanine, dl-","offLabel":[],"synonyms":["DL-Alanine","ALANINE, DL-","(R,S)-Alanine","(+/-)-Alanine"],"timeline":[],"brandName":"Alanine, Dl-","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"In simple terms, DL-Alanine is an amino acid that helps build proteins and provides energy to cells. It's like a building block for the body's proteins and a source of fuel for cells to function properly. While it's not a medication in the classical sense, DL-Alanine may have therapeutic potential in certain conditions.","oneSentence":"DL-Alanine is a non-essential amino acid that plays a role in various cellular processes, including protein synthesis and energy metabolism.","technicalDetail":"DL-Alanine is a racemic mixture of L-alanine and D-alanine, which are both non-essential amino acids. It can be synthesized through various chemical reactions and may have applications in pharmaceuticals, nutrition, or biotechnology."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4306","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DL-Alanine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DL-Alanine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:18:48.284703","biosimilars":[],"competitors":[],"genericName":"dl-alanine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03418779","phase":"PHASE2,PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":["IgA Nephropathy at High Risk of Developing ESRD"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT06403553","phase":"","title":"FC Change From Day 1 to Day 3 Associated With SALD","status":"COMPLETED","sponsor":"Chinese Medical Association","startDate":"2023-01-01","conditions":["Liver Dysfunction"],"enrollment":96,"completionDate":"2024-03-31"},{"nctId":"NCT05101265","phase":"PHASE1","title":"Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment","status":"UNKNOWN","sponsor":"PharmaMar","startDate":"2021-03-09","conditions":["Advanced Solid Tumor","Hepatic Impairment"],"enrollment":24,"completionDate":"2025-06-01"},{"nctId":"NCT05628493","phase":"","title":"Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction","status":"COMPLETED","sponsor":"Chinese Medical Association","startDate":"2022-01-03","conditions":["Gut Microbiota","Intra-abdominal Infections","Acute Gastrointestinal Injury","Sepsis-associated Liver Dysfunction"],"enrollment":20,"completionDate":"2022-09-14"},{"nctId":"NCT05612282","phase":"","title":"The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and the Level of Cardiopulmonary Fitness","status":"COMPLETED","sponsor":"Medical University of Bialystok","startDate":"2016-11-11","conditions":["Obesity, Abdominal"],"enrollment":91,"completionDate":"2017-10-31"},{"nctId":"NCT05214872","phase":"","title":"The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2016-03-25","conditions":["Atherosclerosis of Artery","Inflammation","Chronic Kidney Diseases","Dialysis; Complications","Cardiovascular Diseases"],"enrollment":252,"completionDate":"2020-09-30"},{"nctId":"NCT04271098","phase":"","title":"The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries","status":"COMPLETED","sponsor":"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","startDate":"2012-01-01","conditions":["Hyperbilirubinemia","Hepatic Impairment","Surgery","Cardiac Disease"],"enrollment":340,"completionDate":"2012-09-01"},{"nctId":"NCT03180775","phase":"NA","title":"Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2017-07-01","conditions":["Atherosclerosis","Diet Modification","Serum; Disease"],"enrollment":110,"completionDate":"2018-05-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"NOCODE","UNII":"1FU7983T0U","RXNORM":"1546161","UMLSCUI":"C1648700","PUBCHEM_CID":"602"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":339,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"DL-Alanine is a small molecule compound with unknown target and drug class. Its original development and current ownership are not specified. The compound is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to understand its potential therapeutic applications and risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}